Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval

Raises €200m For Bolt-Ons Or Licensing

Jun 16 2023

• By Kevin Grogan

Almirall — • Source: Almirall

Related Content

Almirall Views Vitiligo As Next Dermatology Opportunity

May 18 2022

Related Companies

Almirall SA

Simcere Pharmaceutical Group

MC2 Therapeutics A/S

Evotec SE

Eli Lilly and Company

Sanofi

Additional Topics

M & A Business Strategies Commercial Deals Dermatology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.